Peter A. Campochiaro
A5085965174- Retinal Diseases and Treatments
- Retinal Development and Disorders
- Retinal and Optic Conditions
- Retinal Imaging and Analysis
- Glaucoma and retinal disorders
- Retinal and Macular Surgery
- Angiogenesis and VEGF in Cancer
- Ocular Diseases and Behçet’s Syndrome
- Intraocular Surgery and Lenses
- Retinopathy of Prematurity Studies
- Cell Adhesion Molecules Research
- Corneal Surgery and Treatments
- Connexins and lens biology
- Lipid metabolism and disorders
- Virus-based gene therapy research
- Retinoids in leukemia and cellular processes
- Vascular Malformations Diagnosis and Treatment
- Photoreceptor and optogenetics research
- Acute Ischemic Stroke Management
- Neuroscience and Neuropharmacology Research
- Ocular Oncology and Treatments
- Ocular Infections and Treatments
- RNA Interference and Gene Delivery
- Cancer, Hypoxia, and Metabolism
- Blood Coagulation and Thrombosis Mechanisms
Johns Hopkins Medicine
2016-2025
Johns Hopkins University
2016-2025
Johns Hopkins Hospital
1992-2021
National Eye Institute
2005-2020
Smith-Kettlewell Eye Research Institute
2014-2019
Applied Genetic Technologies (United States)
2018
Io Therapeutics (United States)
2018
Novartis (Germany)
2018
Allergan (Ireland)
2018
Roche (Switzerland)
2018
Understanding molecular mechanisms regulating angiogenesis may lead to novel therapies for ischemic disorders. Hypoxia-inducible factor 1 (HIF-1) activates vascular endothelial growth (VEGF) gene expression in hypoxic/ischemic tissue. In this study we demonstrate that exposure of primary cultures cardiac and cells hypoxia or AdCA5, an adenovirus encoding a constitutively active form HIF-1alpha, modulates the genes angiogenic factors angiopoietin-1 (ANGPT1), ANGPT2, placental factor,...
We executed a genome-wide association scan for age-related macular degeneration (AMD) in 2,157 cases and 1,150 controls. Our results validate AMD susceptibility loci near CFH ( P < 10 −75 ), ARMS2 −59 C2/CFB −20 C3 −9 CFI −6 ). compared our top findings with the Tufts/Massachusetts General Hospital study of advanced (821 cases, 1,709 controls) genotyped 30 promising markers additional individuals (up to 7,749 4,625 controls). With these data, we identified locus TIMP3 (overall = 1.1 × −11...
Advanced age-related macular degeneration (AMD) is the leading cause of late onset blindness. We present results a genome-wide association study 979 advanced AMD cases and 1,709 controls using Affymetrix 6.0 platform with replication in seven additional cohorts (totaling 5,789 unrelated 4,234 controls). also comprehensive analysis copy-number variations polymorphisms for AMD. Our discovery data implicated between variant hepatic lipase gene (LIPC) high-density lipoprotein cholesterol (HDL)...
Retinitis pigmentosa (RP) is a label for group of diseases caused by large number mutations that result in rod photoreceptor cell death followed gradual cones. The mechanism cone uncertain. Rods are major source oxygen utilization the retina and, after rods die, level outer increased. In this study, we used rd1 mouse model RP to test hypothesis cones die from oxidative damage. A mixture antioxidants was selected try maximize protection against damage achievable exogenous supplements;...
Twenty-eight patients with advanced neovascular age-related macular degeneration (AMD) were given a single intravitreous injection of an E1-, partial E3-, E4-deleted adenoviral vector expressing human pigment epithelium- derived factor (AdPEDF.11). Doses ranging from 106 to 109.5 particle units (PU) investigated. There no serious adverse events related AdPEDF.11 and dose-limiting toxicities. Signs mild, transient intraocular inflammation occurred in 25% patients, but there was severe...
Macular edema is a major cause of vision loss in patients with central retinal vein occlusion (CRVO) or branch (BRVO). It not clear how much the due to hydrodynamic changes from obstruction and chemical mediators. Patients macular CRVO (n = 20) BRVO were randomized receive three monthly injections 0.3 0.5 mg ranibizumab. At primary endpoint, month 3, median improvement letters read at 4 m was 17 0.3-mg group 14 0.5-mg for CRVO, 10 18, respectively group. Optical coherence tomography (OCT)...